Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Although tocilizumab is used in clinical practice for the treatment of cytokine release syndrome (CRS) following ciltacabtagene autoleucel, it may significantly increase the plasma concentrations and pharmacologic effects of ciltacabtagene autoleucel. The exact mechanism of this interaction is unknown, however, in the clinical trials it was shown that ciltacabtagene autoleucel continued to expand and persist following administration of tocilizumab. In the CARTITUDE-1 study, patients treated with tocilizumab (n=68) had an increase in peak plasma concentration (Cmax) and systemic exposure (AUC (0-28d)) of ciltacabtagene autoleucel by 81% and 72%, respectively, compared to patients (n=29) who did not receive tocilizumab. Similarly, an increase in Cmax and AUC0-28d was also observed in patients who received corticosteroids and/or anakinra for treatment of CRS compared to those who did not receive corticosteroids and/or anakinra.

MANAGEMENT: Until more data are available, clinicians should be aware of the potential increase in adverse effects of ciltacabtagene autoleucel following administration of agents used in the treatment of CRS, such as tocilizumab.